The “ALS Centre – Vanvitelli”, part of the First Division of Neurology, University Hospital “Università degli Studi della Campania Luigi Vanvitelli” in Naples (Italy) (new patients/year: about 80; patients in care/year: about 250), is one of the most endorsed ALS centers in Southern Italy, involved in several major national and international clinical trials on ALS. The research activity of this ALS Centre is also performed at the “MRI Research Centre” of the University of Campania “Luigi Vanvitelli”, a centre of excellence based on a collaborative and multi-investigator neuroimaging research environment (including neurologists, neuropsychologists, bioinformaticians, and bioengineers) focused on medical applications of advanced functional and structural magnetic resonance imaging techniques to study brain. Moreover, this ALS centre is involved in several main clinical/research networks: European Reference Network for rare disease (ERN) – Neuromuscular Diseases (Euro-NMD); ITALSGEN (ITalian Consortium for ALS GENetics); NiSALS (Neuroimaging Society in ALS) Consortia; and TRICALS.
| Università degli Studi della Campania Luigi Vanvitelli | |
|---|---|
| Foundation year | 2003 |
| Director | Prof. Gioacchino Tedeschi |
| Principal investigator | Prof. Francesca Trojsi |
| Contact information | |
|---|---|
| Address | Piazza Luigi Miraglia 2, 80138 Naples (Italy) |
| Contact | Prof. Francesca Trojsi |
| Phone | +3908156656 |
| ambulatorio.slavanvitelli@gmail.com | |
| Website | Visit the website |
Publications
- Trojsi F, Di Nardo F, D’Alvano G, et al. Resting state fMRI analysis of pseudobulbar affect in Amyotrophic Lateral Sclerosis (ALS): motor dysfunction of emotional expression. Brain Imaging Behav. 2023;17(1):77-89. doi: 10.1007/s11682-022-00744-4
-
Trojsi F, Siciliano M, Femiano C, et al. Comparative Analysis of C9orf72 and Sporadic Disease in a Large Multicenter ALS Population: The Effect of Male Sex on Survival of C9orf72 Positive Patients. Front Neurosci. 2019;13:485. doi: 10.3389/fnins.2019.00485
-
Trojsi F, Di Nardo F, Santangelo G, et al.Resting state fMRI correlates of Theory of Mind impairment in amyotrophic lateral sclerosis.Cortex 2017;97:1-16. doi: 10.1016/j.cortex.2017.09.016
-
Santangelo G, Siciliano M, Trojano L, Femiano C, Monsurrò MR, Tedeschi G, Trojsi F. Apathy in amyotrophic lateral sclerosis: insights from Dimensional Apathy Scale. Amyotroph Lateral Scler Frontotemporal Degener 2017;18(5-6):434-442. doi: 10.1080/21678421.2017.1313865
-
Trojsi F, Esposito F, de Stefano M, Buonanno D, Conforti FL, Corbo D, Piccirillo G, Cirillo M, Monsurrò MR, Montella P, Tedeschi G. Functional overlap and divergence between ALS and bvFTD. Neurobiol Aging. 2015;36(1):413-23. doi:10.1016/j.neurobiolaging.2014.06.025
For other publications, see: https://www.scopus.com/authid/detail.uri?authorId=14521622200
Restricted information
| Serving population | |
|---|---|
| Serving population | Naples: 3.085.000; Campania: 5.802.000 (additionally, Basilicata 562.869; Calabria 1.947.000) |
| Patient resources | |
|---|---|
| Population based register | No |
| Clinic based register | Yes |
| Geographically matched controls | Yes |
| Number of skin samples | no |
| Number of spinal cord samples | no |
| Number of brain samples | no |
| Number of IPS cell samples | no |
Banks
There are no banks for this centre
| Research activities | |
|---|---|
| Clinical management research | Yes |
| Neuro epidemiology | Yes |
| Neuro physiology | Yes |
| Neuro imaging | Yes |
| Neuro psychology | Yes |
| Neuro pathology | No |
| Genomics | No |
| Transcriptomics | No |
| Metabolomics | No |
Clinical Trials - Industry sponsored
| Name | Type | Patients |
|---|---|---|
| PHOENIX-AMX35 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS) | 19 |
| ADORE- (ALS Deceleration with ORal Edaravone) study | “A multicenter, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of FAB122 in patients with Amyotrophic Lateral Sclerosis” | 7 |
| TUDCA-OLE | Safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS) | 9 |
| TUDCA-ALS | Safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS) | 23 |
| AB 19001 | A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with Riluzole versus placebo in combination with Riluzole in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS) | |
| CARDINALS | A phase 2, randomized, double-blind, placebo- controlled, parallel study to assess the efficacy,safety, tolerability, PK, and biomarker effects of PTC857 in adult subjects with amyotrophic lateral sclerosis | |
| TRIALS | A double-blind, placebo-controlled, exploratory randomised clinical trial to assess the safety and efficacy of IFB-088 plus riluzole 100 mg vs placebo plus riluzole 100 mg in patients with bulbar-onset amyotrophic lateral sclerosis |
Clinical Trials - Investigator initiated
There are no clinical trials for this centre